Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies

被引:405
作者
Haddad, Peter M. [1 ,2 ]
Brain, Cecilia [3 ,4 ]
Scott, Jan [5 ,6 ]
机构
[1] Univ Manchester, Neurosci & Psychiat Unit, Manchester, Lancs, England
[2] Greater Manchester West Mental Hlth NHS Fdn Trust, Cromwell House, Salford M30 0GT, Lancs, England
[3] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Psychosis Clin, Na Ut Teamet, Gothenburg, Sweden
[5] Newcastle Univ, Acad Psychiat, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England
[6] Inst Psychiat, Ctr Affect Disorders, London, England
来源
PATIENT-RELATED OUTCOME MEASURES | 2014年 / 5卷
关键词
adherence; nonadherence; antipsychotics; schizophrenia; long; acting injections; relapse; risk factors;
D O I
10.2147/PROM.S42735
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Nonadherence with medication occurs in all chronic medical disorders. It is a particular challenge in schizophrenia due to the illness's association with social isolation, stigma, and comorbid substance misuse, plus the effect of symptom domains on adherence, including positive and negative symptoms, lack of insight, depression, and cognitive impairment. Nonadherence lies on a spectrum, is often covert, and is underestimated by clinicians, but affects more than one third of patients with schizophrenia per annum. It increases the risk of relapse, rehospitalization, and self-harm, increases inpatient costs, and lowers quality of life. It results from multiple patient, clinician, illness, medication, and service factors, but a useful distinction is between intentional and unintentional nonadherence. There is no gold standard approach to the measurement of adherence as all methods have pros and cons. Interventions to improve adherence include psychoeducation and other psychosocial interventions, antipsychotic long-acting injections, electronic reminders, service-based interventions, and financial incentives. These overlap, all have some evidence of effectiveness, and the intervention adopted should be tailored to the individual. Psychosocial interventions that utilize combined approaches seem more effective than unidimensional approaches. There is increasing interest in electronic reminders and monitoring systems to enhance adherence, eg, Short Message Service text messaging and real-time medication monitoring linked to smart pill containers or an electronic ingestible event marker. Financial incentives to enhance antipsychotic adherence raise ethical issues, and their place in practice remains unclear. Simple pragmatic strategies to improve medication adherence include shared decision-making, regular assessment of adherence, simplification of the medication regimen, ensuring that treatment is effective and that side effects are managed, and promoting a positive therapeutic alliance and good communication between the clinician and patient. These elements remain essential for all patients, not least for the small minority where vulnerability and risk issue dictate that compulsory treatment is necessary to ensure adherence.
引用
收藏
页码:43 / 62
页数:20
相关论文
共 144 条
  • [1] Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables
    Acosta, Francisco J.
    Bosch, Esperanza
    Sarmiento, Gerardo
    Juanes, Nuria
    Caballero-Hidalgo, Araceli
    Mayans, Teresa
    [J]. SCHIZOPHRENIA RESEARCH, 2009, 107 (2-3) : 213 - 217
  • [2] An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis
    Agid, Ofer
    Arenovich, Tamara
    Sajeev, Gautam
    Zipursky, Robert B.
    Kapur, Shitij
    Foussias, George
    Remington, Gary
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (11) : 1439 - 1444
  • [3] Confidence intervals for the number needed to treat
    Altman, DG
    [J]. BRITISH MEDICAL JOURNAL, 1998, 317 (7168) : 1309 - 1312
  • [4] Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care
    Ascher-Svanum, H
    Faries, DE
    Zhu, BJ
    Ernst, FR
    Swartz, MS
    Swanson, JW
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (03) : 453 - 460
  • [5] A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia
    Ascher-Svanum, Haya
    Zhu, Baojin
    Faries, Douglas
    Lacro, Jonathan P.
    Dolder, Christian R.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (07) : 1114 - 1123
  • [6] Au-Yeung KY, 2011, AM J MANAG CARE, V17, pE277
  • [7] Antipsychotic long-acting injections: prescribing practice in the UK
    Barnes, Thomas R. E.
    Shingleton-Smith, Amber
    Paton, Carol
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2009, 195 : S37 - S42
  • [8] Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication
    Beck, Eva-Marina
    Cavelti, Marialuisa
    Kvrgic, Sara
    Kleim, Birgit
    Vauth, Roland
    [J]. SCHIZOPHRENIA RESEARCH, 2011, 132 (01) : 42 - 49
  • [9] NEUROLEPTIC COMPLIANCE AMONG CHRONIC-SCHIZOPHRENIC OUTPATIENTS - AN INTERVENTION OUTCOME REPORT
    BOCZKOWSKI, JA
    ZEICHNER, A
    DESANTO, N
    [J]. JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1985, 53 (05) : 666 - 671
  • [10] Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: A comparison of methods for the measurement of adherence in schizophrenia
    Brain, Cecilia
    Sameby, Birgitta
    Allerby, Katarina
    Lindstrom, Eva
    Eberhard, Jonas
    Burns, Tom
    Waern, Margda
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (02) : 215 - 222